Solution
Industries
Resources
About
Beacon Search

Diabetes Therapies & Diagnostics: Global Markets

Report Code: HLC029C

Publish Date: Jun 2010

Publisher: BCC Publishing

Category: Health Maintenance

Customize This Report

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

  • The global market for therapeutic and diagnostic products for diabetes is valued at $38 billion in 2010. This market is expected to grow at a compound annual growth rate (CAGR) of 6.1% to reach $51.2 billion in 2015.
  • Insulin products, including administration devices, are worth an estimated $16.4 billion in 2010. This sector is expected to reach $22 billion in 2015, a 6.1% compound annual growth rate (CAGR). 
  • Oral hypoglycemic drugs are expected to achieve the highestcompound annual growth rate (CAGR) of 8%, increasing from $10.3 billion in 2010 to $15.1 billion in 2015.

INTRODUCTION 

STUDY GOALS AND OBJECTIVES
 
The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for prescription generic drugs used in the treatment of diabetes and devices and instruments used for diagnosis and monitoring of diabetes. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2015; these are based on epidemiological data and projections, plus information on R&D trends and differential market potential on a country-by-country basis. Healthcare policies, demographics, and the wider economic environment are also taken into account.
 
REASONS FOR DOING THE STUDY
 
It is widely recognized that the prevalence of the commonest type of diabetes mellitus, Type 2, is now reaching epidemic proportions all over the world. Cases of Type 1 DM are also on the increase, although to a less spectacular degree. These trends are of great concern, not only to the individuals concerned, but to governments and providers of healthcare, because the economic consequences of diabetes are vast, as they involve not only the direct burden of managing the disease but also the common and often catastrophic complications including cardiovascular disease, peripheral neuropathy and blindness.
 
Thus the prompt diagnosis and effective treatment of diabetes are essential, not optional, priorities for governments and healthcare agencies. One consequence is that the already large market for diabetes monitoring and treatment will certainly grow in line with increasing incidence and with improvements in diagnosis. Thus diabetes is of great commercial significance to the suppliers of drugs used in treatment and devices needed for monitoring.
 
Among the information needs of companies in this field is accurate and up-to-date assessment of the current extent of the diabetes epidemic, its likely evolution over the next 5 years, and the impact of drugs and technical developments now in the pipeline.
 
SCOPE OF REPORT
 
This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, both in global terms and analyzed by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for main drug and device categories, and breakdowns are provided for several national markets.
 
MARKET ANALYSIS AND FORECASTS
 
Market figures are based on revenues at the manufacturer level and are projected at 2010-dollar value without attempting to predict the effect of inflation/deflation.
 
Therapeutic categories quantified and forecast include insulins and oral hypoglycemic agents, and devices including blood glucose monitors and accessories.
 
METHODOLOGY
 
Primary research includes interviews with leading individuals in relevant companies and medical associations; primary sources of published data include epidemiological and economic studies, company annual reports, SEC filings, and government publications. Secondary sources consist of literature searches, industry journals, and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources, critically assessed by BCC.
 
INTENDED AUDIENCE
 
This report is designed to satisfy the information needs of a wide variety of individuals involved in the diabetes marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning, and sales departments who need readable, comprehensive and up-to-date background on the marketplace in which they are operating.
 
INFORMATION SOURCES
 
Sources of information included marketing strategists, industry executives, government and professional agencies, and surveys of physicians. Company annual reports and SEC filings, journal articles, and data from healthcare institutions were also mined, as well as publications of relevant associations such as the International Diabetes Federation and the American and British Diabetic Associations.
 
ANALYST CREDENTIALS
 
Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the diabetes marketplace covering both therapeutic and monitoring aspects. 
 
BCC ONLINE SERVICES
 
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:  
  • Examine BCC’s complete catalog of Market Research Reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers
DISCLAIMER
 
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
Need pricing for multiple titles, a complete report bundle, or something specially curated to fit your budget? EXPLORE OFFERS
Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
[+] Show Chapter Details
Title/Chapter NamePagesMember Price
Full Report: Diabetes Therapies & Diagnostics: Global Markets150Free
Chapter- 1: INTRODUCTION4Free
Chapter- 2: SUMMARY2Free
Chapter- 3: OVERVIEW6Free
Chapter- 4: ABOUT DIABETES22Free
Chapter- 5: DIABETES THERAPIES21Free
Chapter- 6: ORAL HYPOGLYCEMIC DRUGS5Free
Chapter- 7: DIAGNOSIS AND MONITORING29Free
Chapter- 8: THE DIABETES MARKET17Free
Chapter- 9: NEW APPROACHES TO THE MANAGEMENT OF DIABETES6Free
Chapter- 10: C. CRAMER & CO. GMBH31Free
Chapter- 11: APPENDIX7Free

Related Reports

Track the Latest Global Tariff Developments

In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.

Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.

Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.

With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.

Ready to see what tariff means for your business?

Consult with our experts or request your custom Tariff Impact Brife today

Stay Informed, Stay Competitive

In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.

Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.

Our analysis includes:

  • Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
  • Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
  • Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.

With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.

Don't let tariffs catch you off guard—let our insights guide your strategy.

This is an Excel-only version of the report.

Report Includes

    Total Number of Tables in this Report: 47

  • Summary Table: DIABETES MARKET BREAKDOWN BY PRODUCT GROUPS, THROUGH 2015
  • Table 1: TOTAL DIABETES MARKET
  • Table 2: ADULT DIABETES MARKET, BY REGION
  • Table 3: MAIN BRANDS AND TYPES OF INSULIN
  • Table 4: ORAL DIABETES TREATMENTS
  • Table 5: PREVALENCE OF DIABETES BY REGION, 2010 AND 2030
  • Table 6: PREVALENCE RANGE OF DIABETIC COMPLICATIONS BY REGION, 2006
  • Table 7: MAJOR BRANDS OF INSULIN
  • Table 8: INSULIN PENS
  • Table 9: INSULIN PUMPS
  • Table 10: SULFONYLUREAS
Sample Report

Recent Reports

Global Markets for Catheters

Published - Dec 2025 | Publisher - BCC Publishing | Code - HLC019K

The global market for catheters is expected to grow from $22.8 billion in 2025 and is projected to reach $36 billion by the end of 2030, at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025 to 2030.

Mobile Health (mHealth) Technologies and Global Markets

Published - Nov 2025 | Publisher - BCC Publishing | Code - HLC162D

The global market for Mobile Health (mHealth) Technologies is expected to grow from $91.4 billion in 2025 and is projected to reach $201.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 17.1% during the forecast period of 2025 to 2030.

Global Healthcare Predictive Analytics Markets

Published - Oct 2025 | Publisher - BCC Publishing | Code - HLC311A

According to BCC Research detailed report on healthcare predictive analytics market includes global revenue ($ Million) for the base year of 2024 and estimated data for 2025 and the forecast period 2026 through 2030.

State of the Life Sciences Industry - Third Quarter Review

Published - Oct 2025 | Publisher - BCC Publishing | Code - HLC314A

Explore BCC Research’s Q3 2025 review of the life sciences market. Gain AI-driven insights, sector performance data, and emerging trends shaping global growth.

Patient Monitoring Devices: Global Markets

Published - Sep 2025 | Publisher - BCC Publishing | Code - HLC038H

The global market for patient monitoring devices is expected to grow from $36.7 billion in 2025 and is projected to reach $55.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.7% during the forecast period of 2025 to 2030.

Top Trending Reports

Global Data Center Market

Published - Jul 2025 | Publisher - BCC Publishing | Code - IFT320A

The global market for data centers is expected to grow from $418.2 billion in 2025 and is projected to reach $691.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 10.6% during the forecast period of 2025 to 2030.

Bioprocess Filtration: Global Markets

Published - Oct 2025 | Publisher - BCC Publishing | Code - MDS043B

The global market for bioprocess filtration is estimated to grow from $8.4 billion in 2025 to reach $15.6 billion by 2030, at a compound annual growth rate (CAGR) of 13.1% from 2025 through 2030.

Contract Manufacturing of Medical Devices: Global Markets

Published - Nov 2025 | Publisher - BCC Publishing | Code - MDS039B

The global market for contract manufacturing of medical devices is estimated to grow from $96.4 billion in 2025 to reach $155.2 billion by 2030, at a compound annual growth rate (CAGR) of 10% from 2025 to 2030.

Biological Therapies for Cancer: Technologies and Global Markets

Published - Nov 2025 | Publisher - BCC Publishing | Code - BIO048E

The global biological therapies market for cancer is expected to grow from $157 billion in 2025 and is projected to reach $225 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2025 to 2030.

Immunotherapy Drugs: Global Markets

Published - Nov 2025 | Publisher - BCC Publishing | Code - PHM249B

The global immunotherapy drugs market is expected to grow from $260.7 billion in 2025 and is projected to reach $467.4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% during the forecast period of 2025 to 2030.

Published - Mar-2008| Analyst - Ann Zhai| Code - HLC029B

Report Highlights

  • The global market for diabetes therapeutics and diagnostics increased from $208.5 billion in 2007 to an estimated $213.8 billion by the end of 2008. It should reach $241.9 billion by 2013, a compound annual growth rate (CAGR) of 2.5%.
  • The global diabetes market will become one of the largest healthcare markets over the next five years, due in large part to the epidemic explosion of the type II diabetes population.
  • Over the next five years, market leaders will overcome technology barriers to bring non-invasive, insulin-dependent products to the market.
Published - Oct-2002| Analyst - Amy Adams| Code - HLC029A

Report Highlights

  • The total market for diabetes drugs and devices is estimated at $18 billion in 2002. Growing at an average annual rate (AAGR) of 11.5%, the market is expected to exceed $30.7 billion in 2007.
  • Drug sales in 2002 are expected to be $12.5 billion, increasing to almost $21 billion by 2007 at an AAGR of 10.3%.
  • Insulin was 33% of the market in 2000 and is expected to hold on to that share.
  • Sulfanylureas and biguanides are expected to lose considerable market share to generics, newer classes of drugs, and to the extremely popular thiazolidinediones.
  • The two major diabetes medical devices are glucose monitors and insulin pumps. Glucose monitors are expected to rise at an AAGR of 13.7% to $8 billion by 2007. Insulin pumps are expected to grow to $1.8 billion by 2007 at an AAGR of 18.7%.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Diabetes Therapies & Diagnostics: Global Markets
Customize This Report
Customize Report
Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.
Contact
© 2025 BCC Research
Privacy Policy |Site Map|Terms & Conditions
AI Sentiment